Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-10-28
Recursion Pharmaceuticals, Inc.
Clinical-stage biotechnology company using proprietary data, automated experiments, and AI software to discover and develop small-molecule medicines and partner programs.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Runway Secured, Proof Still Gates the Rerating
The AI-native discovery stack has real data, compute, and partner assets, and fresh capital likely keeps it alive long enough to test them. The upside now depends less on financing and more on whether REC-4881 and a second internal program convert platform promise into approval-shaped proof.

Analysis

Thesis
Fresh capital gives Recursion enough runway to attempt a real business-model upgrade: if its data-and-automation engine yields one approval-shaped internal asset plus repeatable milestone and royalty streams, the stock can rerate from speculative discovery tool to validated AI-enabled biotech platform.
Last Economy Alignment
Cheaper cognition helps because Recursion owns proprietary biology data, automated labs, and drug assets, so value is not just software seats. The cap on alignment is biotech reality: biology and FDA gates still decide when the economics arrive.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.5x (from 5 most recent analyses)
Reasoning
By 2031 the upside case is a blended platform-and-pipeline story: one internally owned commercial asset, a second credible internal or partnered proof point, and a larger base of milestones, royalties, and embedded discovery revenue. That can support meaningful equity upside without heroic assumptions, but the rerating stays constrained until FDA path clarity and repeatability improve.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not that AI gets cheaper; it is that biology, regulators, and pharma partners capture the value before Recursion proves it can keep enough of the economics. The October 2026 financing reduced near-term funding stress, but 2031 upside still hinges on REC-4881 earning an approval-shaped path and at least one follow-on asset or partner program validating repeatability.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own a growing biology data factory, automated labs, and a drug pipeline, so cheaper AI makes their engine more useful rather than cheaper to replace. The risk is that regulators, biology, and pharma partners capture the value before the company proves it can keep enough of the economics.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.32
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case